How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

239 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. New developments in the management of partial-onset epilepsy: role of brivaracetam (PubMed)

observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children. Among the newest anticonvulsant drugs, brivaracetam, a high-affinity synaptic vesicle protein 2A ligand, reported to be 10- to 30-fold more potent than levetiracetam, is highly effective in a broad

Full Text available with Trip Pro

2017 Drug design, development and therapy

162. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs (PubMed)

), treatment with more than one AED, and treatment with a novel AED. The definition for "novel" was newly approved at the time of market entry since 2006 (last 10 years): eslicarbazepine (ESL), lacosamide (LCM), perampanel (PER), and retigabine (RTG). Methods: The analysis was based on a claims data set covering the years 2007 to 2014, provided by AOK PLUS, a German statutory health insurance. Two patient samples were defined: (1) prevalent patients suffering from FE (at least one in- or outpatient

Full Text available with Trip Pro

2017 GMS German Medical Science

163. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate. If adjunctive treatment is ineffective or not tolerated, the guideline recommends that decisions about treatment options should be made after advice from a tertiary epilepsy specialist. Anti- epileptic drugs that may be considered include eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Prescribers should be aware that not all the drugs mentioned above currently have (...) was considered during the development of The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). Based on evidence that was available at the time (up to June 2010), the Guideline Development Group found that zonisamide was one of several anti-epileptic drugs that were more costly and less effective than other cost- effective treatment alternatives. The Guideline Development Group concluded that eslicarbazepine acetate

2014 National Institute for Health and Clinical Excellence - Advice

164. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs (PubMed)

for variable or nonlinear pharmacokinetics; and can be useful in special populations such as pregnancy. This review examines the potential for TDM of newer AEDs such as eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, perampanel, pregabalin, rufinamide, retigabine, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide. We describe the relationships between serum drug concentration, clinical effect, and adverse drug reactions for each AED as well

Full Text available with Trip Pro

2016 Drugs in R&D

165. Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

weeks before to Visit 1; in the case where a new AED regimen has been initiated for a participant, the dose must be stable for at least 8 weeks prior to Visit 1. Only 1 EIAED (defined as carbamazepine, phenytoin, oxcarbazepine, or eslicarbazepine) out of the maximum of 3 AEDs is allowed (A vagal nerve stimulator [VNS] will be counted as one of the 3 allowed AEDs.) Exclusion Criteria: Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta human chorionic

2016 Clinical Trials

166. INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

agents or other agents used in study. Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least 7 days prior to planned start of study treatment. A list of EIAED and other inducers of CYP3A4 is provided. Among non-EIAED, caution is recommended with use of valproic acid due to potential for drug interaction. Participants

2016 Clinical Trials

167. A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

. Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days. Subject is unwilling to refrain from large or daily servings of grapefruits and/or Seville oranges, and their juices beginning with the Baseline Period and throughout the study. A clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Screening Visit, other than epilepsy

2016 Clinical Trials

168. A Study of Abemaciclib in Recurrent Glioblastoma

evidence of 1p/19q co-deletion. IDH1/2 mutation in any prior biopsy. Previous therapies Participants who have received prior treatment with a CDK4/6 inhibitor. Participants who have received anti-VEGF targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL184, sunitinib etc). Concomitant medications Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide

2016 Clinical Trials

169. Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

) Perampanel +phenobarbital, (2) PMP+valproate, (3) PMP+ lamotrigine, (4) PMP + topiramate, (5) PMP + tiagabine, (6) PMP + levetiracetam, (7) PMP + zonisamide, (8) PMP + pregabalin, (9) PMP + lacosamide, (10) PMP+ clobazam, (11) PMP + ezogabine; and (12) PMP + eslicarbazepine. Each group of 6 will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. PMP will be titrated to 8-12 mg/day, with the final dose (...) as "add on" medication. Drug: perampanel Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated. Other Name: Fycompa Active Comparator: eslicarbazepine After

2016 Clinical Trials

170. A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine. Currently receiving or has received stiripentol in the past 21 days prior to Screening. Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days. Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD

2016 Clinical Trials

171. A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome

amount of serotonin agonist or antagonist properties, including serotonin re-uptake inhibition; triptans, atomoxetine, or other centrally-acting noradrenergic agonist; cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates. Subject is currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as maintenance therapy. Subject has a positive result on urine THC Panel or whole blood CBD at the Screening Visit

2016 Clinical Trials

172. An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

-acting anorectic agents; monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist; cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates. Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days

2016 Clinical Trials

173. Partial-onset seizures in epilepsy: zonisamide as monotherapy

effective than other cost-effective treatment alternatives. The Guideline Development Group concluded that eslicarbazepine acetate, lacosamide, pregabalin, tiagabine and zonisamide should be considered only when initial adjunctive therapy options are contraindicated, ineffective or not tolerated. See the introduction for more details. A NICE Pathway on epilepsy brings together all NICE guidance and associated products on epilepsy. Introduction Introduction Epilepsy is a common neurological condition (...) clinical guideline on epilepsy recommends that advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. The NICE technology appraisal on retigabine for the adjunctive treatment of partial onset seizures in epilepsy (NICE technology appraisal guidance 232) recommends retigabine as an option at this point. Product o Product ov verview erview

2013 National Institute for Health and Clinical Excellence - Advice

174. Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V

and older in comparison with the appropriate comparator therapy (ACT). The G-BA specified the following ACT: ? an individual antiepileptic add-on therapy, if medically indicated and if no pharmacoresistance/intolerance and contraindications are known yet, with one of the following drugs: eslicarbazepine (for adults) or gabapentin or lacosamide (for patients aged 16 years and older) or lamotrigine or levetiracetam or oxcarbazepine or pregabalin (for adults) or topiramate or valproic acid or zonisamide (...) Appropriate comparator therapy Extent and probability of added benefit As add-on therapy of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older An individual antiepileptic add-on therapy, if medically indicated and if no pharmacoresistance/intolerance and contraindications are known yet, with one of the following drugs: eslicarbazepine a or gabapentin or lacosamide b or lamotrigine or levetiracetam or oxcarbazepine or pregabalin

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

175. Does medical marijuana work? The answer is (mostly) “no” and “we don’t know”

research. ☛ List of brain tumor patients who died due to opinions based on gossip. Drug Worriers preferred methods of treatment… Epileptic seizures: Aptiom (eslicarbazepine acetate) Who’s Really Fighting Legal Weed ☛ 3/4th of a Century of Gossip and Gutter Science ☛ A Very Lucrative Evil Hoax ☛ Only 13% of the medical schools surveyed mention the endocannabinoid science to our future doctors. Note that’s “mention” GanjaRx. None of the Med Schools teach students, future doctors. Censorship is the same

2015 Respectful Insolence

176. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment

) recommends carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate as adjunctive treatment if monotherapy is ineffective or not tolerated. If adjunctive treatment is ineffective or not tolerated, the guideline recommends that advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered by the specialist at this point in the care pathway are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin (...) or not tolerated, advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide [1][3] Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 15The NICE

2012 National Institute for Health and Clinical Excellence - Advice

177. Genetic, Dietary and Environmental Influences on Vitamin D Metabolism

inducers including: Dexamethasone, Enzalutamide, Lumacaftor, Mitotane, St. John's wort, Bexarotene, Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil Other drugs that will cause a participant to be excluded include: Cholestyramine, Ferric carboxymaltose (treatment of iron deficiency anemia), Dapsone, Metformin Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2015 Clinical Trials

178. Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs

anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate) Drug: anti-epileptic drug Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate) Biological: Blood sampling Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine (...) , oxcarbazepine, eslicarbazepine acetate) Outcome Measures Go to Primary Outcome Measures : Number of patients with viral reactivation of Epstein-Barr Virus [ Time Frame: 3 Months ] Number of patients with viral reactivation of Epstein-Barr Virus is evaluated in patients initiating an anti-epileptic treatment Number of patients with viral reactivation of Human Herpes Virus 6 [ Time Frame: 3 Months ] Number of patients with viral reactivation of Human Herpes Virus 6 is evaluated in patients initiating an anti

2015 Clinical Trials

179. Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

., obstructive airways diseases), eye drops or local injections (e.g., intra-articular) Patient taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, rufinamide carbamazepine, oxcarbazepine, eslicarbazepine, felbamate, and topiramate (only when daily dose exceeds 200 mg). Participant must be off any EIAEDs for at least two weeks prior to starting study Requirement of more than 4 mg dexamethasone daily Patient is being treated at start of study treatment

2015 Clinical Trials

180. Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

. ClinicalTrials.gov Identifier: NCT02491073 Recruitment Status : Completed First Posted : July 7, 2015 Results First Posted : February 5, 2018 Last Update Posted : February 7, 2018 Sponsor: Sunovion Information provided by (Responsible Party): Sunovion Study Details Study Description Go to Brief Summary: The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate (...) interferes with these blood tests, blood samples will be analysed so that researchers can compare different types of lab tests that measure these thyroid hormones. Half of the people who participate in this study will already be taking eslicarbazepine acetate either as a study drug or as a prescription (Part 1) and the other half will be people who do not take eslicarbazepine acetate (Part 2). Condition or disease Intervention/treatment Epilepsy Other: blood draw Detailed Description: Part 1 of the study

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>